CD19+ B cells (Peripheral Blood)

Cryopreserved human CD19+ B cells from adult peripheral blood leukopaks isolated via negative selection. Used for antibody discovery, BCR sequencing, vaccine development, B-cell lymphoma research, autoimmune studies, and anti-CD19 CAR-T target validation. IRB-approved with Certificate of Analysis on every lot.

Description

Quick summary

B cells isolated from peripheral blood leukopaks via CD19+ immunomagnetic enrichment. Sourced from OrganaBio’s 1,000+ qualified, recallable donor pool with 14-marker infectious disease screening and NGS HLA typing across HLA-A, B, C, DR, DQ, DP. Available as RUO and cGMP from the same donor pool under one quality system, so programs moving from preclinical to clinical do not requalify donors. Best fit: B-cell biology research, antibody-mediated cell therapy programs, and B-cell-targeted CGT preclinical work.

LeukoPAC-B-PB – Cryopreserved Human CD19+ B Cells (Adult Peripheral Blood)

LeukoPAC-B-PB delivers cryopreserved human CD19+ B cells isolated from adult peripheral blood leukopaks via negative selection. Negative selection depletes non-B cells and leaves B cells untouched, preserving native CD19 and other surface markers without crosslinking — critical for functional receptor studies, signaling assays, and any work where native biology matters.

Applications

OrganaBio CD19+ B cells are used to isolate and sequence B cell receptors and generate monoclonal antibodies, evaluate humoral immune responses and memory B cell formation, provide normal B cell controls for B-cell lymphoma, CLL, and multiple myeloma drug development, investigate B cell-mediated autoimmunity and BAFF signaling, serve as high-purity CD19+ targets for anti-CD19 CAR-T cytotoxicity and co-culture killing assays, and profile naive, memory, transitional, and plasmablast subsets with frequencies reported on every CoA.

Donor Program

Cells are isolated from OrganaBio’s recallable donor program of 500+ donors. Same-donor repeat collections support longitudinal studies, process development with consistent starting material, and matched donor panels across product lines.

Quality and Documentation

Donors are screened under IRB-approved consent and FDA 21 CFR 1271 donor eligibility criteria. Each lot ships with a Certificate of Analysis including donor screening, B cell subset frequencies, immunophenotyping by flow cytometry, HLA Class I and II typing, and cryopreservation details. FDA Registered. cGMP available.

Configurations

Available cryopreserved at 5×10⁶ and 10×10⁶ cells per vial. Custom vialing, custom donor criteria, and fresh format are available on request. Cells are for preclinical research use only and not for use in humans.

For full specifications, applications, and the interactive product overview, see the CD19+ B Cells product page.


Need custom B cell isolation or specific donor criteria? Through our CDMO services, we deliver custom isolation (specific subsets, fresh format, disease-state donors) with full quality documentation. Explore Cell Processing Services →

Frequently Asked Questions

How are CD19+ B cells isolated?

CD19+ B cells are isolated from peripheral blood leukopaks via immunomagnetic enrichment, providing a high-purity B cell population suitable for downstream applications.

What B cell research is this product suited for?

CD19+ B cells from peripheral blood are common starting material for B-cell biology research, antibody-mediated cell therapy programs, B-cell-targeted CGT preclinical work, and humoral immunity studies.

What screening do donors undergo?

Each donor is screened against 14 infectious disease markers per 21 CFR 1271, plus CMV, EBV, and alloantibodies. NGS HLA typing across HLA-A, B, C, DR, DQ, DP is provided.

Are CD19+ B cells available at cGMP grade?

Yes. The same donor pool serves both RUO and cGMP grades under one quality system, supporting RUO-to-clinical transitions without donor requalification.

Can I request specific donor characteristics?

Yes. Customer-selectable donor characteristics include gender, age, race, ethnicity, blood type, BMI, smoking status, and CMV/EBV status, plus HLA-specific donor selections.